| Austin N Dehart, MD | |
|
1920 E Cambridge Ave Ste 201, Phoenix, AZ 85006-1462 | |
| (602) 933-3277 | |
| (602) 933-4326 |
| Full Name | Austin N Dehart |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology - Pediatric Otolaryngology |
| Location | 1920 E Cambridge Ave Ste 201, Phoenix, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093152951 | NPI | - | NPPES |
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588654016 PECOS PAC ID: 4082528955 Enrollment ID: O20031219000706 |
News Archive
Unexpected patterns emerged in the microbial and viral communities of mice with intestinal inflammation during a study that examined the intestinal tracts of diseased and healthy mice.
The Children's Hospital and Denver Health have signed an official Affiliation Agreement to leverage the substantial strengths of both institutions to provide outstanding programs in pediatric patient care, education, research and advocacy. Under the agreement, two of the largest pediatric health care providers in the region are able to provide improved access for patients, share best practices and more efficiently use resources.
A new international collaboration reports that the compound called TCMDC-135051 is capable of preventing the synthesis of a protein that is required for growth in Plasmodium falciparum, one of the species of the Plasmodium parasite that causes malaria. The study, reported in the journal Science, could lead to the development of a new antimalarial drug.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Doctors have been dispensing advice to heart failure patients and for the first time researchers have found that it works. While self-care is believed to improve heart failure outcomes, a highlight of the recent American Heart Association scientific statement on promoting heart failure self-care was the need to establish the mechanisms by which self-care may influence neurohormonal, inflammatory, and hemodynamic function.
› Verified 2 days ago
| Entity Name | University Of Arkansas For Medical Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346230968 PECOS PAC ID: 4082528955 Enrollment ID: O20040115000431 |
News Archive
Unexpected patterns emerged in the microbial and viral communities of mice with intestinal inflammation during a study that examined the intestinal tracts of diseased and healthy mice.
The Children's Hospital and Denver Health have signed an official Affiliation Agreement to leverage the substantial strengths of both institutions to provide outstanding programs in pediatric patient care, education, research and advocacy. Under the agreement, two of the largest pediatric health care providers in the region are able to provide improved access for patients, share best practices and more efficiently use resources.
A new international collaboration reports that the compound called TCMDC-135051 is capable of preventing the synthesis of a protein that is required for growth in Plasmodium falciparum, one of the species of the Plasmodium parasite that causes malaria. The study, reported in the journal Science, could lead to the development of a new antimalarial drug.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Doctors have been dispensing advice to heart failure patients and for the first time researchers have found that it works. While self-care is believed to improve heart failure outcomes, a highlight of the recent American Heart Association scientific statement on promoting heart failure self-care was the need to establish the mechanisms by which self-care may influence neurohormonal, inflammatory, and hemodynamic function.
› Verified 2 days ago
| Entity Name | Arkansas Childrens Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598773079 PECOS PAC ID: 2769477744 Enrollment ID: O20040419000796 |
News Archive
Unexpected patterns emerged in the microbial and viral communities of mice with intestinal inflammation during a study that examined the intestinal tracts of diseased and healthy mice.
The Children's Hospital and Denver Health have signed an official Affiliation Agreement to leverage the substantial strengths of both institutions to provide outstanding programs in pediatric patient care, education, research and advocacy. Under the agreement, two of the largest pediatric health care providers in the region are able to provide improved access for patients, share best practices and more efficiently use resources.
A new international collaboration reports that the compound called TCMDC-135051 is capable of preventing the synthesis of a protein that is required for growth in Plasmodium falciparum, one of the species of the Plasmodium parasite that causes malaria. The study, reported in the journal Science, could lead to the development of a new antimalarial drug.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Doctors have been dispensing advice to heart failure patients and for the first time researchers have found that it works. While self-care is believed to improve heart failure outcomes, a highlight of the recent American Heart Association scientific statement on promoting heart failure self-care was the need to establish the mechanisms by which self-care may influence neurohormonal, inflammatory, and hemodynamic function.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Austin N Dehart, MD 3200 E Camelback Rd Ste 250, Phoenix, AZ 85018-2327 Ph: (602) 933-1814 | Austin N Dehart, MD 1920 E Cambridge Ave Ste 201, Phoenix, AZ 85006-1462 Ph: (602) 933-3277 |
News Archive
Unexpected patterns emerged in the microbial and viral communities of mice with intestinal inflammation during a study that examined the intestinal tracts of diseased and healthy mice.
The Children's Hospital and Denver Health have signed an official Affiliation Agreement to leverage the substantial strengths of both institutions to provide outstanding programs in pediatric patient care, education, research and advocacy. Under the agreement, two of the largest pediatric health care providers in the region are able to provide improved access for patients, share best practices and more efficiently use resources.
A new international collaboration reports that the compound called TCMDC-135051 is capable of preventing the synthesis of a protein that is required for growth in Plasmodium falciparum, one of the species of the Plasmodium parasite that causes malaria. The study, reported in the journal Science, could lead to the development of a new antimalarial drug.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Doctors have been dispensing advice to heart failure patients and for the first time researchers have found that it works. While self-care is believed to improve heart failure outcomes, a highlight of the recent American Heart Association scientific statement on promoting heart failure self-care was the need to establish the mechanisms by which self-care may influence neurohormonal, inflammatory, and hemodynamic function.
› Verified 2 days ago
Dr. Shawn Michael Stevens, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 | |
Charles R Orozco, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4250 E Camelback, Suite K-250, Phoenix, AZ 85018 Phone: 602-253-9026 Fax: 602-252-6391 | |
John David Macias, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1515 N 9th St, Suite B, Phoenix, AZ 85006 Phone: 602-257-4228 Fax: 602-252-6416 | |
Dr. Michael L Hinni, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5779 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
Randy Oppenheimer, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 2601 E Roosevelt St, Department Of Surgery, Phoenix, AZ 85008 Phone: 602-344-5608 Fax: 602-344-1299 | |
Griffin Santarelli, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 |